Physician profile
Mark Herbst
NPI 1578516811
$4,293.63
in general payments reported to CMS, 2019-2025
25 companies · $108 in 2025
The $108 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,644 · 2020: $1,434 · 2021: $582 · 2022: $212 · 2023: $95.32 · 2024: $218 · 2025: $108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $421.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $420.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $771.38 | 2019-2022 | |
| Harmony Biosciences LLC | $747.15 | 2020-2025 | Wakix |
| Novo Nordisk INC | $632.20 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $396.91 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $294.32 | 2019-2024 | Trintellix |
| Lundbeck LLC | $285.80 | 2019-2021 | |
| Indivior INC. | $144.23 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $127.80 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $127.09 | 2019-2020 | |
| Shire North American Group INC | $81.65 | 2019 | |
| Janssen Pharmaceuticals, INC | $80.89 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $78.80 | 2021-2022 | |
| Adlon Therapeutics L.P. | $72.38 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $72.28 | 2019 | |
| Abbvie INC. | $66.83 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $66.56 | 2019-2020 | |
| Neos Therapeutics, LP | $64.02 | 2019 | |
| Allergan, INC. | $47.18 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $28.58 | 2025 | |
| Bausch Health US, LLC | $25.30 | 2019 | |
| Vertical Pharmaceuticals, LLC | $22.22 | 2020 | |
| Ironshore Pharmaceuticals INC. | $19.69 | 2019 | |
| Zyla Life Sciences, INC. | $13.91 | 2019 | |
| Alkermes, INC. | $13.33 | 2021 | |
| Currax Pharmaceuticals LLC | $13.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Herbst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.